Induced Locomotor Hyperactivity on Ethanol Withdrawal Syndrome in Rats is Inhibited by Quetiapine

H. Serdar Gergerlioğlu 1 * , Haluk A. Savaş 2, Mehmet Boşnak 3, Cahit Bağcı 3, Yasemin Baltacı 3, M. Tuba Bilgiç 3, Mahmut Bulut 2, Nurşadan Gergerlioğlu 4, I. Tayfun Uzbay 5
More Detail
1 Selçuk University Medical School, Dep. of Physiology Konya, Türkiye
2 Gaziantep University Medical School, Dep. of Psychiatry Gaziantep, Türkiye
3 Gaziantep University Medical School, Dep. of Physiology Gaziantep, Türkiye
4 Beyhekim State Hospital Division of Pathology, Konya, Türkiye
5 GATA University Medical School, Dep. of Pharmacology Ankara, Türkiye
* Corresponding Author
EUR J BASIC MED SCI, Volume 2, Issue 4, pp. 112-117.
Download Full Text (PDF)


Our aim is to investigate the effects of two atypical antipsychotics; quetiapine and olanzapine on locomotor activity that is a sign of ethanol withdrawal syndrome in rats. Adult male Wistar rats were subjects. Ethanol (7.2%, v/v) was given to rats by a liquid diet for 30 days. Control rats were pair fed an isocaloric liquid diet containing sucrose as a caloric substitute to ethanol. Quetiapine (10 mg/kg), olanzapine (5 mg/kg) and saline were injected to the rats intraperitoneally 7 days after ethanol withdrawal syndrome and the last one 30 min before ethanol withdrawal testing. After 2nd hour of ethanol withdrawal, rats were observed for 5 min and withdrawal signs that included locomotor hyperactivity were recorded. We have found increased vertical and horizontal locomotor activity in ethanol withdrawal group to control and reduced vertical and horizontal locomotor activity in quetiapine-injected rats. In olanzapine injected rats were seen no reduced locomotor activity. Significant inhibitory effects were produced by quetiapine on the signs of ethanol withdrawal. Our results suggest that acute quetiapine treatment has some beneficial efects on ethanol withdrawal in rats. Thus, this drug may be useful for treatment of ethanol withdrawal syndrome.


Gergerlioğlu HS, Savaş HA, Boşnak M, Bağcı C, Baltacı Y, Bilgiç MT, et al. Induced Locomotor Hyperactivity on Ethanol Withdrawal Syndrome in Rats is Inhibited by Quetiapine. Eur J Basic Med Sci. 2012;2(4):112-7.


  • O’brien CP. Drug addiction and abuse . In: Hardman JG, Limbird LE. (Eds) Goodman and Gilman’s The pharmacological basis of therapeutics 10th ed 2001; 621-43.
  • Thompson W.L. management of alcohol withdrawal syndromes. Arch Int Med 1978; 138:278-83.
  • Majchrowicz E. Induction of physical dependence upon ethanol and the associated behavioral changes in rats. Psychopharmacologia 1975; 43:1993-6.
  • Majchrowicz E. Comparison of ethanol withdrawal syndrome in humans and rats. Adv Exp Med Biol 1977; 85B:15-23.
  • Carlsson A, Engel J, Svensson T.H. Inhibition of ethanolinduced excitation in mice and rats by alpha-methyl-ptyrosine. Psychopharmacologia 1972; 26:307-12.
  • Frye G.D., Breese G.R. An evaluation of the locomotor stimulating action of ethanol in mice and rats. Psychopharmacology 1981; 75: 372-9.
  • Uzbay IT, Kayaalp SO. A modified liquid diet of chronic ethanol administration: validation by ethanol withdrawal syndrome in rats. Pharmacol Res 1995; 31:37–42.
  • Schuckit MA, Smith TL, Radziminski S, Heyneman EK. Behavioral symptoms and psychiatric diagnoses among 162 children in nonalcoholic or alcoholic families. Am J Psychiatry 2000; 157:1881-3.
  • Weissman MM, Myers JK. Clinical depression in alcoholism. Am J Psychiatry 1980; 137:372–3.
  • Miguel-Hidalgo J, Rajkowska G. Comparison of prefrontal cell pathology between depression and alcohol dependence. Journal of Psychiatric Research 2003; 37:411–20.
  • Favre JD, Guelfi-Sozzi C, Delalleau B, Loo H. Tianeptine and alcohol dependence. European Neuropsychopharmacology 1997; 7(Suppl.3):347–51.
  • Myrick H, Brady KT, Malcolm R. New developments in the pharmacotherapy of alcohol dependence. American Journal of Addictions 2001; 10 (Suppl.):3–15.
  • Roy A, Virkunnen M, Linnolia M. Reduced central serotonin turnover in subgroup of alcoholics. Biological Psychiatry 1987; 11:173–7.
  • Murphy JM, McBridge WJ, Lumeng L, Li T-K. Contents of monoamines in forebrain regions of alcohol-preferring and non- preferring lines of rats. Pharmacology, Biochemistry and Behavior 1987; 26:389–92.
  • Quintin P, Thomas P. Efficacy of atypical antipsychotics in depressive syndromes. Encephale 2004; 30:583-9.
  • Ishak WW, Rapaport MH, Gotto JG. The Effectiveness of Atypical Antipsychotic Medications in Depressive Disorders. Current Psychiatry Reports 2004; 6:422-4.
  • Klein N, Sacher J, Wallner H, Tauscher J, Kasper S. Therapy of treatment resistant depression: focus on the management of TRD with atypical antipsychotics. CNS Spectr 2004; 9:823-32.
  • Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, Suppes T, Calabrese JR. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry 2005; 66:40-8.
  • Uzbay IT, Erden BF, Tapanyiğit EE, Kayaalp SO. Nitric oxide synthase inhibition attenuates signs of ethanol withdrawal in rats. Life Sci 1997; 61:2197–209.
  • Kayir H, Uzbay T. Effects of clozapine on ethanol withdrawal syndrome in rats. Alcohol and alcoholism. 2008; 43:619-25.
  • Uzbay TI. Atypical antipsychotic drugs and ethanol withdrawal syndrome: a review. Alcohol and alcoholism 2012; 47:33-41.
  • Kuriyama K, Ohkuma S. Alterations in the function of cerebral neurotransmitter receptors during the establishment of alcohol dependence: neurochemical aspects. Alcohol Alcohol 1990; 25:239–49.
  • Uzbay IT. Serotonergic antidepressants and ethanol withdrawal syndrome: a review. Alcohol Alcohol 2008; 43:15-24.
  • Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000; 26:441–9.
  • Ingman K, Honkanen A, Hyytia P, Huttunen MO, Korpi ER. Risperidone reduces limited access alcohol drinking in alcohol-preferring rats. Eur j of pharmacol 2003; 468:121-75.
  • Ingman K, Korpi ER. Alcohol drinking of alcohol-preferring AA rats is differentially affected by clozapine and olanzapine. Eur j of pharmacol 2006; 534:133-40.
  • Kayir H, Uzbay T. Effects of clozapine on ethanol withdrawal syndrome in rats. Alcohol Alcohol 2008; 43:619–25.
  • Unsalan N, Saglam E, Kayir H, Uzbay T. Effects of olanzapine on ethanol withdrawal syndrome in rats. Eur j of pharmacol 2008; 579:208-14.
  • Celikyurt IK, Kayir H, Ulak G, Erden FB, Ulusoy GK, Uzbay TI. Effects of risperidone, quetiapine and ziprasidone on ethanol withdrawal syndrome in rats. Progress in neuro-psychopharmacology & biological psychiatry 2011; 35:528-36.
  • Uzbay IT, Usanmaz SE, Tapanyigit EE, Aynacioglu S, Akarsu ES. Dopaminergic and serotonergic alterations in the rat brain during ethanol withdrawal: association with behavioral signs. Drug and alcohol dependence 1998; 53:39-47.
  • Uzbay IT, Usanmaz SE, Akarsu ES. Effects of chronic ethanol administration on serotonin metabolism in the various regions of the rat brain. Neurochemical research 2000; 25:257-62.
  • Uzbay IT, Saglam E, Kayir H, Celik T, Beyazyurek M. Effects of fluoxetine on ethanol withdrawal syndrome in rats. J Psychiatr Res 2004; 38:445-50.
  • Saglam E, Uzbay IT, Kayir H, Celik T, Beyazyurek M. Effects of venlafaxine on ethanol withdrawal syndrome in rats. Fundam Clin Pharmacol 2004; 18:693-8.
  • Janiri L, Gobbi G, Mannelli P, Pozzi G, Serretti A, Tempesta E. Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics Int Clinical Psychopharmacol 1996; 11:109–17.
  • Helzer JE, Pryzbeck TR. The co-occurrence of alcoholism with other psychiatric disorders in the general population and its impact on treatment. J Stud Alcohol 1988; 49:219-24.
  • Lal H, Prather PL, Rezazadeh SM. Potential role of 5-HT1C and/or 5-HT2 receptors in the mianserin-induced prevention of anxiogenic behaviors occurring during ethanol withdrawal. Alcohol Clin Exp Res 1993; 17:411–7.
  • Overstreet DH, Knapp DJ, Moy SS, Breese GR. A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats. Psychopharmacology 2003; 167:344–52.
  • Overstreet DH, Knapp DJ, Angel RA, Navarro M, Breese GR. Reduction in repeated ethanol- withdrawal-induced anxiety-like behavior by site-selective injections of 5-HT1A and 5-HT2C ligands. Psychopharmacology 2006; 187:1-12.